Teratogen update: Methotrexate

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 94, Issue 4, 2012, Pages 187-207

  Hyoun, Sara C ^a   Običan, Sarah G ^b   Scialli, Anthony R ^b,c  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c TETRA TECH INC   (United States)

Author keywords

Abortion; Aminopterin; Dihydrofolate reductase; Ectopic pregnancy; Malformations; Methotrexate; Teratology

Indexed keywords

1 (4 TOSYL) 3,4,4 TRIMETHYLIMIDAZOLIDINE; AMINOPTERIN; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; HYDROXYCHLOROQUINE; IMIDAZOLE DERIVATIVE; MERCAPTOPURINE; METHOTREXATE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; VINCRISTINE;

ACCESSORY SPLEEN; AFFECT; ALOPECIA; AMINOPTERIN SYNDROME; ANENCEPHALUS; ANGIOMA; ANISOCORIA; ARRHINENCEPHALY; ARTICLE; ATRIOVENTRICULAR CANAL; AUDITORY CANAL; BACTERIAL INFECTION; BIRTH DEFECT; BLEEDING; BLEPHAROPHIMOSIS; BONE MALFORMATION; BRACHYCEPHALY; BRAIN DISEASE; BRAIN MALFORMATION; BREAST CANCER; BREAST CARCINOMA; CEREBELLUM HYPOPLASIA; CHORIOCARCINOMA; CHOROID PLEXUS CYST; CLEFT LIP PALATE; CLINODACTYLY; CLUBFOOT; CORPUS CALLOSUM AGENESIS; CRANIOFACIAL MALFORMATION; CRANIOFACIAL SYNOSTOSIS; CRYPTORCHISM; CYST; DEXTROCARDIA; DIAGNOSTIC ERROR; DIAPHRAGM HERNIA; DOLICHOCEPHALY; DUBOWITZ SYNDROME; ECTOPIC PREGNANCY; ECTRODACTYLY; EMBRYO DEATH; EMBRYOPATHY; EMBRYOTOXICITY; ENDOCARDIAL CUSHION DEFECT; EPIBLEPHARON; EPICANTHUS; EXPERIMENTAL CAT; EXPERIMENTAL MONKEY; EXPERIMENTAL MOUSE; EXPERIMENTAL RABBIT; EXPERIMENTAL RAT; EXTERNAL EAR MALFORMATION; EYE MALFORMATION; EYELID DISEASE; FACIAL NERVE PARALYSIS; FALLOT TETRALOGY; FETUS MALFORMATION; FIBULA; FINGER MALFORMATION; FONTANEL; FOOT MALFORMATION; FOREBRAIN MALFOMATION; FUNNEL CHEST; GENITAL MALFORMATION; GREAT VESSELS TRANSPOSITION; GROWTH RETARDATION; GYNECOMASTIA; HAIR DISEASE; HAND MALFORMATION; HEAD CIRCUMFERENCE; HEART ATRIUM SEPTUM DEFECT; HEART RIGHT VENTRICLE DOUBLE OUTLET; HEART VENTRICLE SEPTUM DEFECT; HEMIMELIA; HOLOPROSENCEPHALY; HORSESHOE KIDNEY; HORSESHOE LUNG; HUMAN; HYDATIDIFORM MOLE; HYDROCEPHALUS; HYDRONEPHROSIS; HYPERTELORISM; HYPODACTYLY; HYPOPLASIA; HYPOSPADIAS; INFLAMMATORY DISEASE; INGUINAL HERNIA; INTESTINE MALROTATION; INTRAUTERINE GROWTH RETARDATION; IRRITABILITY; JAW MALFORMATION; JOINT HYPERMOBILITY; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY MALFORMATION; KIDNEY PELVIS; KYPHOSIS; LATERAL BRAIN VENTRICLE; LEUKEMIA; LIMB MALFORMATION; LOW SET EAR; LUNG ARTERY PRESSURE; LUNG MALFORMATION; MALFORMATION SYNDROME; MENINGOMYELOCELE; MENTAL DEFICIENCY; MESOMELIA; METACARPAL BONE; METATARSUS VARUS; MICROCEPHALY; MICROGNATHIA; MICROPENIS; MICROPHTHALMIA; MICROTIA; MOUTH MALFORMATION; MULTICYSTIC DYSPLASTIC KIDNEY; MUSCLE HYPOTONIA; NAIL HYPOPLASIA; NIPPLE MALFORMATION; NONHUMAN; NOSE MALFORMATION; NYSTAGMUS; OLFACTORY BULB; ORBIT DISEASE; OSSIFICATION; OXYCEPHALUS; PALPEBRAL FISSURE ANOMALY; PANCYTOPENIA; PATENT FORAMEN OVALE; PENIS DISEASE; PHOCOMELIA; PLAGIOCEPHALY; POLYDACTYLY; PREGNANCY TERMINATION; PREMATURITY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PTOSIS; PUBIC BONE; PULMONARY VALVE ATRESIA; PULMONARY VALVE STENOSIS; RADIUS; RECTUS ABDOMINIS MUSCLE DIASTASIS; RESPIRATORY DISTRESS SYNDROME; RETROGNATHIA; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RIB MALFORMATION; SCOLIOSIS; SCROTUM DISORDER; SIDE EFFECT; SKULL DEFECT; SKULL SUTURE; SUBLUXATION; SYNDACTYLY; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; THERAPEUTIC ABORTION; THORAX MALFORMATION; THYMUS DISEASE; TOE MALFORMATION; TRICHIASIS; UMBILICAL ARTERY; UMBILICAL HERNIA; UMBILICAL MALFORMATION; UNDERWEIGHT; VERTEBRA MALFORMATION; WEBBED NECK; WEIGHT GAIN;

ABNORMALITIES, DRUG-INDUCED; ABNORMALITIES, MULTIPLE; AMINOPTERIN; ANIMALS; FEMALE; FETAL DISEASES; FOLIC ACID ANTAGONISTS; HUMANS; METHOTREXATE; MICE; MICE, INBRED C57BL; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY, ECTOPIC; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; TERATOGENS; TETRAHYDROFOLATE DEHYDROGENASE;

ANIMALIA; MUS; ORYCTOLAGUS CUNICULUS; RATTUS; VERTEBRATA;

EID: 84859562288     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.23003     Document Type: Article

References (56)

1. American College of Obstetricians and Gynecologists. 2008. ACOG Practice Bulletin No. 94: medical management of ectopic pregnancy. Obstet Gynecol 111: 1479-1485.
2. Adam MP, Manning MA, Beck AE, et al. 2003. Methotrexate/misoprostol embryopathy: report of four cases resulting from failed medical abortion. Am J Med Genet A 123: 72-78.
3. Addar MH. 2004. Methotrexate embryopathy in a surviving intrauterine fetus after presumed diagnosis of ectopic pregnancy: case report. J Obstet Gynaecol Can 26: 1001-1003.
4. Avilés A, Diaz-Maqueo JC, Talavera A, et al. 1991. Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children. Am J Hematol 36: 243-248.
5. Barnhart KT. 2009. Clinical practice. Ectopic pregnancy. N Engl J Med 361: 379-387.
6. Bawle EV, Conard JV, Weiss L. 1998. Adult and two children with fetal methotrexate syndrome. Teratology 57: 51-55.
7. Berry CL. 1971. Transient inhibition of DNA synthesis by methotrexate in the rat embryo and foetus. J Embryol Exp Morphol 26: 469-474.
8. Briggs GG, Freeman RK, Yaffe SJ. 2011. Aminopterin. In: Drugs in pregnancy and lactation. 9th ed. Lippincott Williams and Wilkins. pp. 54-55.
9. Brudie LA, Ahmad S, Radi MJ, et al. 2011. Metastatic choriocarcinoma in a viable intrauterine pregnancy treated with EMA-CO in the third trimester. a case report. J Reprod Med 56: 359-363.
10. Buckley LM, Bullaboy CA, Leichtman L, Marquez M. 1997. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 40: 971-973.
11. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. 2003. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 30: 241-246.
12. Chapa JB, Hibbard JU, Weber EM, Abramowicz JS, Verp MS. 2003. Prenatal diagnosis of methotrexate embryopathy. Obstet Gynecol 101(5 Pt 2): 1104-1107.
13. Corona-Rivera JR, Rea-Rosas A, Santana-Ramírez A, et al. 2010. Holoprosencephaly and genitourinary anomalies in fetal methotrexate syndrome. Am J Med Genet Part A 152: 1741-1746.
14. Correa A, Cragan JD, Kucik JE, Alverson CJ, Gilboa SM, Balakrishnan R, Strickland MJ, Duke CW, O'Leary LA, Riehle-Colarusso T, Siffel C, Gambrell D, Thompson D, Atkinson M, Chitra J. 2007. Metropolitan Atlanta Congenital Defects Program 40th Anniversary Edition Surveillance Report. Appendix A. Birth Defects Res (A) 79: 94-177.
15. Darab DJ, Minkiff R, Sciote J, Sulik KK. 1987. Pathogenesis of median facial clefts in mice treated with methotrexate. Teratology 36: 77-86.
16. Del Campo M, Kosaki K, Bennett FC, Jones KL. 1999. Developmental delay in fetal aminopterin/methotrexate syndrome. Teratology 60: 10-12.
17. DeSesso JM. 1981. Comparative ultrastructural alterations in rabbit limb-buds after a teratogenic dose of either hydroxyurea or methotrexate. Teratology 23: 197-215.
18. DeSesso JM, Goeringer GC. 1991. Amelioration by leucovorin of methotrexate developmental toxicity in rabbits. Teratology 43: 201-215.
19. DeSesso JM, Goeringer GC. 1992. Methotrexate-induced developmental toxicity in rabbits is ameliorated by 1-(p-tosyl)-3, 4, 4-trimethylimidazolidine, a functional analog for tetrahydrofolate-mediated one-carbon transfer. Teratology 45: 271-283.
20. DeSesso JM, Jordan RL. 1977. Drug-induced limb dysplasias in fetal rabbits. Teratology 15: 199-212.
21. Donnenfeld AE, Pastuszak A, Noah JS, et al. 1994. Methotrexate exposure prior to and during pregnancy. Teratology 49: 79-81.
22. Elmazar MMA, Nau H. 1992. Methotrexate increases valproic acid-induced developmental toxicity, in particular neural tube defects in mice. Teratog Carcinog Mutagen 12: 203-210.
23. Farber S, Diamond LK. 1948. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 238: 787-793.
24. Feldkamp M, Carey JC. 1993. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology 47: 533-539.
25. Georgiou EX, Domoney C, Savage P, Stafford M. 2011. Heterotopic abdominal pregnancy with persistent trophoblastic tissue. Acta Obstet Gynecol Scand 90: 551-553.
26. Giannakopoulou C, Manoura A, Hatzidaki E, et al. Multimodal cancer chemotherapy during the first and second trimester of pregnancy: a case report. Eur J Obstet Gynecol Reprod Biol 2000; 95-97.
27. Goffman D, Cole DS, Bobby P, et al. 2006. Failed methotrexate termination of pregnancy: a case report. J Perinatol 26: 645-647.
28. Granzow JW, Thaller SR, Panthaki Z. 2003. Cleft palate and toe malformations in a child with fetal methotrexate exposure. J Craniofac Surg 14: 747-748.
29. Hahn I, Hoffman RS, Nelson LS. 2001. Leucovorin rescue for malicious abortion attempt with methotrexate. J Toxicol Clin Toxicol 2001; 39: 507.
30. Jones KL. 2006. Fetal aminopterin/methotrexate syndrome. In: Smith's recognizable patterns of human malformation, 6th ed. Philadelphia: Elsevier Saunders. pp. 658-659.
31. Jordan RL, Wilson JG, Schumacher HJ. 1977. Embryotoxicity of the folate antagonist methotrexate in rats and rabbits. Teratology 15: 73-80.
32. Khera KS. 1976. Teratogenicity studies with methotrexate, aminopterin, and acetylsalicylic acid in domestic cats. Teratology 14: 21-28.
33. Kozma C, Ramasethu J. 2011. Methotrexate and misoprostol teratogenicity: further expansion of the clinical manifestations. Am J Med Genet Part A 155: 1723-1728.
34. Krähenmann F, Østensen M, Stallmach T, et al. 2002. In utero first trimester exposure to low-dose methotrexate with increased fetal nuchal translucency and associated malformations. Prenat Diagn 22: 489-490.
35. Lewden B, Vial T, Elefant E, et al; French Network of Regional Pharmacovigilance Centers. 2004. Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study. J Rheumatol. 31: 2360-2365.
36. Moreno-Ruiz NL, Borgatta L, Yanow S, et al. 2007. Alternatives to mifepristone for early medical abortion. Int J Gynaecol Obstet 96: 212-218.
37. Mulholland CP, Pollock TJ. 2011. The Peters anomaly following antenatal exposure to methotrexate and hydroxychloroquine. Can J Ophthalmol 46: 289-290.
38. Newman CGH. 1985. Teratology update: clinical aspects of thalidomide embryopathy-a continuing preoccupation. Teratology 32: 133-134.
39. Nguyen C, Duhl AJ, Escallon CS, Blakemore KJ. 2002. Multiple anomalies in a fetus exposed to low-dose methotrexate in the first trimester. Obstet Gynecol 99: 599-602.
40. Nurmohamed L, Moretti ME, Schechter T, et al. 2011. Outcome following high-dose methotrexate in pregnancies misdiagnosed as ectopic. Am J Obstet Gynecol 205: 533.e1-e3.
41. Østensen M, Hartmann H, Salvesen K. 2000. Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. J Rheumatol 27: 1872-1875.
42. Østensen M, von Esebeck M, Villiger PM. 2007. Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease. J Rheumatol 34: 1266-1269.
43. Piggott KD, Dorbello A, Riddle E, DeCampli W. 2011. Congenital cardiac defects: a possible association of aminopterin syndrome and in utero methotrexate exposure? Pediatr Cardiol 32: 518-520.
44. Poggi SH, Ghidini A. 2011. Importance of timing of gestational exposure to methotrexate for its teratogenic effects when used in setting of misdiagnosis of ectopic pregnancy. Fertil Steril 96: 669-671.
45. Seidahmed MZ, Shaheed MM, Abdulbasit OB, et al. 2006. A case of methotrexate embryopathy with holoprocencephaly, expanding the phenotype. Birth Defects Res A Clin Mol Teratol 76: 138-142.
46. Skalko RG, Gold MP. 1974. Teratogenicity of methotrexate in mice. Teratology 9: 159-164.
47. Sutton C, McIvor RS, Vagt M, Doggett B, Kapur RP. 1998. Methotrexate-resistant forms of dihydrofolate reductase protects transgenic murine embryos from teratogenic effects of methotrexate. Pediatr Dev Pathol 1: 503-512.
48. Thiersch JB. 1952. Therapeutic abortions with a folic acid antagonist, 4-aminopteroylglutamic acid (4-amino P.G.A) administered by the oral route. Am J Obstet Gynecol 63: 1298-1304.
49. Tshibangu K, Leroy F, Doumont-Meyvis M, et al. 1975. Effects of amethopterin (methotrexate) on the evolution of pregnancy in rats. Toxicology 4: 65-73.
50. Usta IM, Nassar AH, Yunis KA, Abu-Musa AA. 2007. Methotrexate embryopathy after therapy for misdiagnosed ectopic pregnancy. Int J Gynaecol Obstet 99: 253-255.
51. Wheeler M, O'Meara P, Stanford M. 2002. Fetal methotrexate and misoprostol exposure: the past revisited. Teratology 66: 73-76.
52. Wilson JG. 1971. Use of rhesus monkeys in teratological studies. Fed Proc 30: 104-109.
53. Wilson JG, Scott WJ, Ritter EJ, Fradkin R. 1979. Comparative distribution and embryotoxicity of methotrexate in pregnant rats and rhesus monkeys. Teratology 19: 71-78.
54. Woo DC, McClain RM, Hoar RM. 1978. Potentiation of methotrexate embryolethality by aspirin in rats. Teratology 17: 37-42.
55. Yedlinsky NT, Morgan FC, Whitecar PW. 2005. Anomalies associated with failed methotrexate and misoprostol termination. Obstet Gynecol 105(5 Pt 2): 1203-1205.
56. Zand DJ, Blance C, Coleman B, et al. 2003. In utero methotrexate exposure resulting in long bone aplasia. Am J Hum Genet 73( 5 Suppl): 591.